Introduction

The acceleration of bone remodelling, with an excessive osteoclastogenesis or activation of mature osteoclasts, causes the loss of bone mass which is implicated in bone resorption diseases. Conventional therapies are expensive and limited by systemic toxicity and low drug bioavailability. Alternative treatments that are not only effective but also administered employing formulations and dosages different from conventional ones, may improve adherence to therapy, having a positive influence on clinical outcomes. Experimental evidence have attributed antiproliferative and apoptosis inducing activity on different cell lines (including osteoclast precursors or mature osteoclasts) to four plants used in Ayurvedic medicine: Asparagus racemosus (AR), Emblica officinalis (EO), Hemidesmus indicus (HI) and Rubia cordifolia (RC) These properties could be helpful in the treatment of some bone resorption diseases. In order to clarify the possible therapeutic effects of these compounds, the anti-osteoclast activity of their decoctions were evaluated.